Avacta Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments
SummaryMarketline's Avacta Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Avacta Group Plc since January2007.
Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.
Key Highlights
This report includes Avacta Group Plc's contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.
The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Avacta Group Plc. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.
Scope
- Provides intelligence on Avacta Group Plc's M&A, strategic partnerships and alliances, capital raising and private equity transactions.
- Detailed reports of various financial transactions undertaken by Avacta Group Plc and its subsidiaries since 2007.
- Information about key financial and legal advisors for Avacta Group Plc's financial deals transactions.
- Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.
Reasons to Buy
- Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances.
- Form an independent opinion about Avacta Group Plc’s growth strategies through the organic and inorganic activities undertaken since 2007.
- Track your competitors’ business structure and growth strategies.
CVS Group operates animal veterinary practices, complementary veterinary diagnostic businesses, pet crematoria and an on-line pharmacy and retail business. Co. has four main business areas: Veterinary Practice, which includes first-opinion and referral practices providing specialist treatment for companion animals, equine and farm animals; Laboratory, which provides diagnostic services to CVS veterinary practices and third parties; crematoria, which provides pet cremation and clinical waste services to its veterinary practices, third-party practices and directly to pet owners; and Animed Direct, which consists of its on-line pharmacy and retail business.
Dechra Pharmaceuticals is engaged in the veterinary pharmaceuticals and related products business. Co. has three reportable segments: European Pharmaceuticals, manufactures and markets Companion Animal, Equine and Food producing Animal Products and also includes third party manufacturing; North American Pharmaceuticals, which consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel, which sells Companion Animal, Equine Products and Food producing Animal Products in those territories; and Pharmaceuticals Research and Development, which includes all of Co.'s pharmaceutical research and development activities.
Scancell Holdings is engaged in the discovery and development of novel vaccines for the treatment of cancer based on its proprietary immuno-oncology platforms, ImmunoBody®, and Moditope®. Co.'s ImmunoBody® consist of SCIB1 melanoma vaccine, and SCIB2 lung cancer vaccine. Co. has a collaboration partnership to evaluate the use of its SCIB2 to treat non-small cell lung cancer. Co.'s Moditope® technology is a vaccine platform that targets neo-epitopes to overcome immune suppression induced by tumour cells. Co.'s Moditope® product, Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide for the treatment of breast cancer, ovarian cancer and sarcoma.
MarketLine, a world-leading provider of commercial intelligence, has over 400 experienced analysts, consultants, and researchers with regional and sector expertise in market sizing, competitor tracking, socio and macro economics, and business drivers.
For more than 15 years MarketLine has supported the research needs of investment banks, corporations, professional services firms, and academia with a unique mix of company, industry, country, city and financial data for every major industry and marketplace.
MarketLine’ holistic business intelligence report collection includes:
Industry Intelligence
‒ Industry Profiles
‒ Market Forecasts
‒ Porter’s Five Forces Analysis
Company Intelligence
‒ Company Profiles
‒ SWOT Analysis
‒ Financial Deals
Country and City Intelligence
‒ Country and City Profiles
‒ PEST/PESTLE Analysis
‒ Socio and macro-economic indicators
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.